(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 19.08% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Pulmonx's revenue in 2026 is $91,664,000.On average, 8 Wall Street analysts forecast LUNG's revenue for 2026 to be $3,964,293,685, with the lowest LUNG revenue forecast at $3,662,241,655, and the highest LUNG revenue forecast at $4,267,830,608. On average, 7 Wall Street analysts forecast LUNG's revenue for 2027 to be $4,820,953,334, with the lowest LUNG revenue forecast at $4,042,209,332, and the highest LUNG revenue forecast at $6,547,141,707.
In 2028, LUNG is forecast to generate $6,587,151,330 in revenue, with the lowest revenue forecast at $4,801,979,698 and the highest revenue forecast at $9,718,213,681.